©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 7, 2017; 23(5): 776-791
Published online Feb 7, 2017. doi: 10.3748/wjg.v23.i5.776
Published online Feb 7, 2017. doi: 10.3748/wjg.v23.i5.776
To screen or not to screen? Celiac antibodies in liver diseases
Janaína Luz Narciso-Schiavon, Leonardo Lucca Schiavon, Department of Internal Medicine, Division of Gastroenterology, Federal University of Santa Catarina, Santa Catarina 88040-900, Brazil
Author contributions: All authors contributed to the writing, analysing and revision of the manuscript.
Conflict-of-interest statement: None declared.
Correspondence to: Janaína Luz Narciso-Schiavon, MD, PhD, Department of Internal Medicine, Division of Gastroenterology, Federal University of Santa Catarina, R. Prof. Ma Flora Pausewang s/no, 3º andar, Trindade, Florianópolis, Santa Catarina 88040-900, Brazil. janaina.narciso@uol.com.br
Telephone: +55-48-37219149 Fax: +55-48-37219014
Received: September 27, 2016
Peer-review started: September 28, 2016
First decision: November 9, 2016
Revised: November 28, 2016
Accepted: December 8, 2016
Article in press: December 8, 2016
Published online: February 7, 2017
Processing time: 117 Days and 7.1 Hours
Peer-review started: September 28, 2016
First decision: November 9, 2016
Revised: November 28, 2016
Accepted: December 8, 2016
Article in press: December 8, 2016
Published online: February 7, 2017
Processing time: 117 Days and 7.1 Hours
Core Tip
Core tip: Liver involvement in celiac disease (CD) has been reported for more than four decades. However, CD antibodies are seldom investigated by clinicians in routine hepatology consultations. In this article, we perform extensive literature review on liver and CD and evaluate if one should screen for celiac antibodies in various liver diseases and clinical settings.